【13 Performance】Watsons Pharmaceuticals earned 11 times more last year; revenue from China's oncology products increased by 23% in the second half compared to the first half.

SocialAnxietyStaker · 2026-03-05T13:01:40+00:00

Hutchison MediPharma will achieve a profit of $457 million in 2025, an 11.11-fold increase year-on-year, with no final dividends paid. Despite a 12.96% decrease in annual revenue, sales of oncology products continued to grow overseas. Sales in the Chinese market have rebounded, R&D expenditure decreased, and plans are in place to strengthen the development and collaboration of the ATTC platform. The cash balance reached $1.4 billion, which is favorable for future growth.

SocialAnxietyStaker

2026-03-05 13:01:40

Abstract generation in progress

Hutchison MediPharma (00013) Announces that by 2025, profits will reach $457 million, a significant increase of 11.11 times year-on-year. Basic earnings per share are $0.53, with no final dividend declared. Hutchison MediPharma Non-Executive Chairman Dan Eldar stated that the company is at a critical turning point, having realigned its commercial team to better address current environmental challenges and promote sales growth in the Chinese market, which has already shown significant results in Q2 2025.

Due to regulatory and commercialization challenges faced in the first half of 2025, annual revenue decreased by 12.96% year-on-year to $549 million. However, sales of oncology products increased by 4.73% year-on-year to $524 million, mainly driven by overseas sales of colorectal cancer drug FRUZAQLA, which grew by 26% year-on-year to $366 million.

Sales of Oncology Products in Mainland China Decline

In mainland China, sales of oncology products including colorectal cancer drug Avelumab, pancreatic cancer drug Sutimda, and lung cancer drug Worryza fell by 13%, 45%, and 36% respectively last year. The lymphoma drug Darvacet, approved in March last year, has seen continuous sales growth since July, with a full-year increase of 1.56 times to $2.5 million. The company pointed out that oncology product revenue in China experienced a turning point in the second half of 2025, with sales in the second half increasing by 23% compared to the first half.

ATTC Seeks Collaboration with Multinational Pharma Companies

During the period, R&D expenses decreased by 30.08% year-on-year to $148 million. Eldar mentioned that the Antibody-Targeted Conjugate (ATTC) platform has entered clinical trials, paving the way for many new pipeline candidates to advance into clinical development. This year, the company will seek potential collaborations with multinational pharmaceutical companies to develop ATTC candidates. Additionally, its large-molecule technology platform has transitioned from drug discovery to clinical development, with two candidates currently in clinical trials. This is seen as a significant opportunity for the company to deepen collaborations with top global industry players and increase R&D investment to accelerate the realization of the platform’s broad therapeutic potential.

Cash Balance of $1.4 Billion

Hutchison MediPharma Acting CEO and CFO Zheng Zefeng added that the company’s cash balance has reached $1.4 billion, which will help accelerate the development of the ATTC technology platform and its innovative candidate drugs.

He pointed out that the company’s next wave of products is currently under regulatory review, such as the immune thrombocytopenia drug Solupinib and intrahepatic cholangiocarcinoma drug Fanregratinib, which are expected to further enhance sales and profitability visibility in the coming years.

Financial Hot Talk

Middle East conflict threatens oil supply. Will oil prices break $100? Could this impact the global economy?

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.